Vantage logo

Zogenix’s pain is GW Pharma’s gain

A regulatory misstep puts Zogenix even further behind its epilepsy rival GW Pharma, which in turn is waiting for data that could give it another boost. 

Vantage logo

Déjà vu for Aveo and tivozanib

As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.

Vantage logo

Alkermes gets decisive thumbs down

ALKS 5461 is headed back to the clinic or scrapheap, raising questions over whether Alkermes should remain in mental health drug development.